Report: Mylan Might See Higher Bid From Teva

Mylan NV MYL shares were unmoved by an unconfirmed report Friday that it might get a sweetened bid from Teva Pharmaceutical Industries Ltd. TEVA.

Teva is reportedly trying to rustle up bank financing of about $25 billion to increase its unsolicited bid for Mylan, according to the Bloomberg report.

Teva is undecided on the amount by which it may increase its Mylan offer, according to the report.

Mylan recently rejected a $40 billion bid from Teva and remains committed to its plan to acquire Perrigo Co. PRGO for $32.7 billion. Perrigo has rejected the offer.

Teva reiterated its offer for Mylan on Tuesday.

Israeli-based Teva is now in talks to obtain the added funding from banks including Barclays, Citigroup, HSBC Holdings and Bank of America, according to sources Bloomberg didn't identify.

Mylan traded recently at $70.84, up $0.49; Teva gained $0.79 to $60.83.